Apellis Pharmaceuticals, Inc.
APLS
$23.19
-$0.30-1.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 7.01% | -21.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 7.01% | -21.52% | |||
| Cost of Revenue | -33.23% | 3.05% | |||
| Gross Profit | 112.65% | -51.72% | |||
| SG&A Expenses | 1.39% | 6.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.33% | 4.79% | |||
| Operating Income | 60.05% | -218.48% | |||
| Income Before Tax | 54.63% | -154.76% | |||
| Income Tax Expenses | 36.66% | 19.23% | |||
| Earnings from Continuing Operations | 54.30% | -153.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 54.30% | -153.69% | |||
| EBIT | 60.05% | -218.48% | |||
| EBITDA | 60.38% | -222.28% | |||
| EPS Basic | 54.50% | -151.83% | |||
| Normalized Basic EPS | 54.85% | -152.93% | |||
| EPS Diluted | 54.50% | -151.83% | |||
| Normalized Diluted EPS | 54.85% | -152.93% | |||
| Average Basic Shares Outstanding | 0.46% | 0.75% | |||
| Average Diluted Shares Outstanding | 0.46% | 0.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||